Medtronic PLC
$ 96.75
-1.89%
24 Feb - close price
- Market Cap 126,478,770,000 USD
- Current Price $ 96.75
- High / Low $ 98.73 / 96.57
- Stock P/E 27.54
- Book Value 37.95
- EPS 3.58
- Next Earning Report 2026-05-20
- Dividend Per Share $2.83
- Dividend Yield 2.92 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 105.55
- 52 Week Low 77.73
About
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Analyst Target Price
$111.77
Quarterly Earnings
| Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-11-18 | 2025-08-19 | 2025-05-21 | 2025-02-18 | 2024-11-19 | 2024-08-20 | 2024-05-23 | 2024-02-20 | 2023-11-21 | 2023-08-22 | 2023-05-25 |
| Reported EPS | 1.36 | 1.36 | 1.26 | 1.62 | 1.39 | 1.26 | 1.23 | 1.46 | 1.3 | 1.25 | 1.2 | 1.57 |
| Estimated EPS | 1.33 | 1.31 | 1.23 | 1.58 | 1.36 | 1.25 | 1.2 | 1.45 | 1.26 | 1.18 | 1.11 | 1.56 |
| Surprise | 0.03 | 0.05 | 0.03 | 0.04 | 0.03 | 0.01 | 0.03 | 0.01 | 0.04 | 0.07 | 0.09 | 0.01 |
| Surprise Percentage | 2.2556% | 3.8168% | 2.439% | 2.5316% | 2.2059% | 0.8% | 2.5% | 0.6897% | 3.1746% | 5.9322% | 8.1081% | 0.641% |
Next Quarterly Earnings
| Apr 2026 | |
|---|---|
| Reported Date | 2026-05-20 |
| Fiscal Date Ending | 2026-04-30 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-16 | 2025-10-17 | 2025-07-11 | 2025-04-11 | 2025-01-10 | 2024-10-11 | 2024-07-12 | 2024-04-12 | 2024-01-12 | 2023-10-13 |
| Amount | $0.71 | $0.71 | $0.71 | $0.7 | $0.7 | $0.7 | $0.7 | $0.69 | $0.69 | $0.69 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDT
2026-02-24 21:50:34
Medtronic (MDT) reported mixed Q3 FY26 results with higher sales but lower net income and reaffirmed its full-year EPS guidance. The company is navigating margin pressures, a $381 million antitrust verdict, and the restructuring of its diabetes business, including a planned spin-off. These factors are central to its investment narrative, balancing diversification and dividend history against ongoing operational challenges.
2026-02-24 20:35:36
A wrongful death lawsuit has been filed against Abbott Laboratories regarding its FreeStyle Libre 3 and Libre 3 Plus glucose monitors, alleging defects linked to multiple deaths and serious injuries. This legal action, following previous FDA safety alerts, questions Abbott's risk oversight and product quality controls, especially concerning its significant continuous glucose monitoring franchise. Investors are advised to monitor regulatory responses, company disclosures, and potential impacts on Abbott's compliance costs and market position against competitors.
2026-02-24 17:32:02
Insulet (NasdaqGS:PODD) has significantly increased its share buyback authorization and extended the program's duration, signaling management's belief that its shares are undervalued. The stock is currently trading around $249.38, which is about 30% below the analyst price target and 16.1% below Simply Wall St's fair value estimate. Despite recent mixed performance, the expanded buyback suggests a commitment to returning capital to shareholders, though investors are advised to consider profit margins and potential impacts on reinvestment.
2026-02-24 16:50:44
Medtronic's diabetes spinoff, MiniMed, has priced its initial public offering (IPO) at up to $784 million, planning to offer 28 million shares at $25 to $28 each. The new company is expected to be the only one in the market offering both insulin pumps and continuous glucose monitors, aiming for a competitive advantage through integrated diabetes therapy solutions. MiniMed generated $2.7 billion in revenue in fiscal 2025 and reported a net loss of $198 million, with Medtronic retaining approximately 90% ownership post-IPO.
2026-02-24 15:49:47
Boston Scientific (BSX) has seen recent share price declines but is considered undervalued based on two valuation approaches. A Discounted Cash Flow (DCF) analysis estimates BSX's intrinsic value at US$82.81 per share, indicating it's trading at a 10.2% discount. The Price-to-Earnings (P/E) ratio also suggests the stock is slightly undervalued compared to its Fair Ratio.
2026-02-24 15:35:06
Danaher (NYSE:DHR) has agreed to acquire health tech firm Masimo, integrating it as a standalone operating unit within its diagnostics portfolio. This all-cash $9.9 billion deal aims to significantly expand Danaher's presence in patient monitoring and clinical diagnostics, drawing attention from investors in medical technology and diagnostics. The acquisition could reshape Danaher's market position, deepen its data capabilities, and potentially increase exposure to device cycles and reimbursement dynamics while offering opportunities for cross-selling and strengthening its ecosystem.
